The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult). These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes. An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease. According to our (Global Info Research) latest study, the global Microbiome Therapeutics market size was valued at USD 94 million in 2022 and is forecast to a readjusted size of USD 825.1 million by 2029 with a CAGR of 36.5% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes. The Application of Microbiome Therapeutics includes CDI, IBD, Orphan Drug, Immuno-oncology and Others, and the proportion of R&D Investmen for CDI is about 52%. For Microbiome Therapeutics Pipeline Product, SER-109, ABI-H0731, ribaxamase, SYN-010 have the most investment in research, there are in Phase 3, PHASE 1b and Phase 2. North American is the largest market, It occupy nearly 37% market share. Following North American, Europe is the second largest market with the consumption market share of 30%. Market competition is not intense. Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon and PureTech are the leading Developers in the industry, with about 60% market shares. This report is a detailed and comprehensive analysis for global Microbiome Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided. Key Features: Global Microbiome Therapeutics market size and forecasts, in consumption value ($ Million), 2018-2029 Global Microbiome Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2018-2029 Global Microbiome Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029 Global Microbiome Therapeutics market shares of main players, in revenue ($ Million), 2018-2023 The Primary Objectives in This Report Are: To determine the size of the total market opportunity of global and key countries To assess the growth potential for Microbiome Therapeutics To forecast future growth in each product and end-use market To assess competitive factors affecting the marketplace This report profiles key players in the global Microbiome Therapeutics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon and PureTech, etc. This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence. Market segmentation Microbiome Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets. Market segment by Type Upper GIT Lower GIT Market segment by Application C. difficile Infection (CDI) Inflammatory Bowel Disease (IBD) Orphan Drug Immuno-oncology Others Market segment by players, this report covers Seres Therapeutics Assembly Biosciences Synthetic Biologics Interxon PureTech Synlogic Enterome BioScience 4D Pharma Second Genome AOBiome C3 Jian Rebiotix MicroBiome Therapeutics LLC Metabiomics Ritter Pharmaceuticals Symberix OpenBiome Azitra Symbiotix Biotherapies Osel Metabogen Market segment by regions, regional analysis covers North America (United States, Canada, and Mexico) Europe (Germany, France, UK, Russia, Italy, and Rest of Europe) Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific) South America (Brazil, Argentina and Rest of South America) Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa) The content of the study subjects, includes a total of 13 chapters: Chapter 1, to describe Microbiome Therapeutics product scope, market overview, market estimation caveats and base year. Chapter 2, to profile the top players of Microbiome Therapeutics, with revenue, gross margin and global market share of Microbiome Therapeutics from 2018 to 2023. Chapter 3, the Microbiome Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast. Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029. Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Microbiome Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029. Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War Chapter 12, the key raw materials and key suppliers, and industry chain of Microbiome Therapeutics. Chapter 13, to describe Microbiome Therapeutics research findings and conclusion.
1 Market Overview 1.1 Product Overview and Scope of Microbiome Therapeutics 1.2 Market Estimation Caveats and Base Year 1.3 Classification of Microbiome Therapeutics by Type 1.3.1 Overview: Global Microbiome Therapeutics Market Size by Type: 2018 Versus 2022 Versus 2029 1.3.2 Global Microbiome Therapeutics Consumption Value Market Share by Type in 2022 1.3.3 Upp
